Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + trastuzumab
- Development stage
- Phase 3
- Lead developer
- Roche
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of capecitabine, an oral fluoropyrimidine chemotherapy agent, and trastuzumab, a monoclonal antibody that targets HER2 receptors. This combination is used primarily for the treatment of HER2-positive metastatic breast cancer. Capecitabine is converted to 5-fluorouracil in tumor cells, interfering with DNA synthesis, while trastuzumab binds to the HER2 receptor on cancer cells, inhibiting cell growth and proliferation.
- Brand names
- Xeloda + Herceptin
02
Targets
FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)ERBB2 (Erb-b2 receptor tyrosine kinase 2)TS (Thymidylate synthase)
Beyond the preview
Go deeper on capecitabine + trastuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + trastuzumab.